Leveraging RWE To Support Market Access Decision-Making

Beyond clinical trials, real-world evidence (RWE) is revolutionizing how new drugs are positioned, reimbursed, and accessed. RWE provides crucial insights into a medication's effectiveness in diverse patient populations, helping pharmaceutical companies differentiate their products and payers make informed formulary decisions.

This article explores how Cencora's experts leverage RWE, combining diverse data sources like medical claims, patient registries, and even wearable devices. They discuss how this data-driven approach helps identify optimal patient populations, supports label expansions, and ultimately accelerates market access.

Discover how RWE is overcoming challenges like data complexity and regulatory uncertainty to drive better patient outcomes and inform strategic decision-making in the pharmaceutical industry. Read more to learn about the future of RWE and its potential to reshape the healthcare landscape.